Clinical Research Directory

Inclusion Criteria: * Histologically proven pancreatic adenocarcinoma ; * Age ≥ 18 years ; * WHO score 0-1 ; * Locally advanced according to NCCN 1.2015 recommendations; * Non-metastatic after TAP scan and MRI of the liver ; * CA 19.9 \< 1000 IU/mL ; * Completion of at least 4 cycles of induction chemotherapy (Folfirinox and/or Gemzar-Abraxane) with a maximum of 8 courses ; * Women of childbearing potential must have a pregnancy blood test within a maximum of 7 days before starting the study treatment. A negative result must be documented before study treatment is started. Women without reproductive potential are postmenopausal women or women who have undergone permanent sterilisation (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) ; * Effective contraception for women of childbearing age ; * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures ; * Patient has given informed, written and express consent ; * Patient affiliated to a French health insurance scheme. Exclusion Criteria: * Other concomitant cancer or history of cancer, with the exception of treated cervical cancer in situ, basal or squamous cell skin carcinoma, superficial bladder tumour (Ta, Tis, and T1) or a tumour with a good prognosis treated curatively without chemotherapy and without evidence of disease in the 3 years prior to inclusion ; * History of radiotherapy with a foreseeable overlap with the radiotherapy treatment under study (history of abdominal irradiation) ; * Contraindication to MRI and MRI-guided radiotherapy (claustrophobia, presence of metallic elements etc...) ; * History of chronic inflammatory disease of the colon or rectum ; * Women who are pregnant, parturient or breastfeeding ; * Any other serious concomitant and unbalanced disease or disorder that may interfere with the patient's participation in the study and his/her safety during the study (e.g. severe hepatic, renal, pulmonary, metabolic, or psychiatric disorders) ; * Legal incapacity (patient under curatorship or guardianship) ; * History of severe and unexpected reactions to treatment containing a fluoropyrimidine ; * Hypersensitivity to capecitabine, to used excipients or to fluorouracil ; * Known complete deficiency of dihydropyrimidine dehydrogenase (DPD) ; * In patients with severe leukopenia, neutropenia or thrombocytopenia ; * In patients with severe hepatic insufficiency ; * Patients with severe renal insufficiency (creatinine clearance less than 30 mL/min) ; * Recent or concomitant treatment with brivudine.